Welichem Begins Patient Enrollment for Phase IIb Trial of WBI-1001 Creams in
Patients with Atopic Dermatitis (A Common Type of Eczema)
BURNABY, BC,
The study is being conducted at three centers across
The Company is also pleased to announce today that
"
ON BEHALF OF THE BOARD Dr. Tan Xiangdong, Chairman of the Board About Welichem Biotech Inc.
Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancer.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements.
%SEDAR: 00021386E
For further information: Liren Tang, Chief Executive Officer. Tel.: (604) 432-1703, Email:[email protected]
Share this article